Navigation Links
LightLab Imaging Leads Global Advancement of Intracoronary Imaging
Date:1/5/2009

WESTFORD, Mass., Jan. 5 /PRNewswire/ -- LightLab Imaging Inc. today announced several important developments in the field this past year that are the culmination of sustained clinical and technology investment by the company. These advances significantly increase the Company's leadership position in intravascular optical coherence tomography, or OCT. OCT is a new high-resolution, high-speed imaging modality that uses advanced photonics for intravascular imaging and tissue characterization. LightLab is using its unique portfolio of highly proprietary technology to design, manufacture and sell intravascular OCT systems that aid interventional cardiologists in the diagnosis and treatment of coronary artery disease.

With a ten-fold higher resolution than intravascular ultrasound, OCT is poised to become the gold standard imaging modality when high resolution images are essential. As of December 31, 2008, Light Lab has more than 300 M2(TM) and M2x(TM) systems in 20 countries in Europe, Asia, the Middle East and South America. Per-system catheter utilization increased 45% in 2008 over 2007, and the number of imaging catheters sold in 2008 increased 90% from 2007 levels. The number of clinical OCT procedures using LightLab Imaging OCT systems has now surpassed 10,000, providing LightLab with unsurpassed "real-world" experience with OCT.

"From all perspectives, LightLab is recognized as the clear global leader in intravascular OCT," said David Kolstad, LightLab Imaging's President and CEO. "During 2008, we continued to execute strategies that will further extend our leadership position in the year ahead. Among them, we expect to shortly announce the initiation of patient enrollment in a major clinical study of our intravascular OCT system here in the United States. In addition, in October we became the only reimbursed intravascular OCT imaging product in the world when we received a favorable reimbursement coverage decision from the Japanese Ministry of Health, Labor and Welfare that provided OCT payment at a level above IVUS."

OCT is rapidly becoming indispensable in the evaluation of coronary stents. This November, OCT was recognized in a special meeting article in the European Heart Journal in which the European Society of Cardiology and the European Association for Percutaneous Cardiovascular Interventions together with European regulatory bodies recommended OCT as a modality for assessing stent coverage and neointima formation in clinical studies designed to support regulatory submissions for new stents in Europe.

Clinical Research Leadership

During 2008, clinicians continued to demonstrate the enhanced value of LightLab by deploying its M2 and M2x OCT imaging systems in critically important clinical studies. All OCT images acquired in the groundbreaking Horizons AMI OCT data study, presented at the 2008 American Heart Association Congress, were generated using LightLab Imaging OCT systems. At TCT in October, LightLab Imaging OCT systems were used in 30 clinical presentations and 18 abstracts, more than 3 times the number of presentations and abstracts than all other competitors combined. A number of additional important studies are expected in the coming year, further establishing the important role of OCT in interventional cardiology.

"We have exciting plans for 2009, in cardiology and other applications. We continue to build on our proprietary technology platform and leadership position, with increased levels of investment ensuring that our OCT offerings remain the products and services of choice by the world's foremost clinicians," added Mr. Kolstad.

About LightLab Imaging

LightLab Imaging Inc. is the pioneer and leader in the development of Optical Coherence Tomography (OCT) for vascular and other applications. With a proprietary platform and catheter technology protected by over 50 patents, OCT is a high-resolution imaging modality that applies advanced photonics to medical imaging. With the ability to resolve real-time images to 15 micrometers, the LightLab Imaging OCT Imaging Systems offer physicians more information, and more precise information, than ever before available.

     Contact:
     Brad Cilley
     Vice President, LightLab Imaging Inc.
     978/399-1025

     Press:
     Steve DiMattia
     646/201-5445

'/>"/>
SOURCE LightLab Imaging
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. Nikon Instruments A1 Confocal Laser Microscope Series With NIS-Elements C Software Delivers Fully Integrated Comprehensive Confocal Imaging Capabilities
2. Nikon Instruments Introduces Exclusive VAAS Detector Imaging Method for Confocal Microscopy
3. Applied Precision Introduces New Super-Resolution Imaging System Doubling Resolution of Traditional Microscopes
4. Imaging Diagnostic Systems CT Laser Mammography (CTLM) Technology Featured in Peer-Reviewed Journal
5. Imaging in Living Color with Siemens Molecular CT
6. Imaging Diagnostic Systems CT Laser Mammography (CTLM(R)) System Featured at the 94th Annual Radiological Society of North America (RSNA) Conference
7. Imaging Diagnostic Systems is Recognized for Its Advanced Engineering in Time-Resolved Techniques by the US Patent Office
8. Diagnostic Imaging to Deliver Its 11th Annual Webcast of Key Events Taking Place at RSNA 2008
9. Technical Note: E-PAGE(TM) 48- and 96-Well Gels on the Odyssey(R) Infrared Imaging System
10. TRIDELITY Display Solutions Partners With Two Of The World's Leading Imaging Software Companies
11. Diagnostic Imaging - Enters Purchase Agreement to Acquire Teleradiology Company
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/23/2017)... LOS ANGELES , Feb. 23, 2017  Capricor Therapeutics, ... cardiac and other medical conditions, today announced that Linda Marbán, ... at two upcoming investor conferences: Cowen ... 2017 at 10:00 am ET Boston, MA ... 14, 2017 at 9:00 am PT (12:00 pm ET) ...
(Date:2/23/2017)... and SAN FRANCISCO , Feb. 23, ... medicine company, and Beyond Type 1, a not-for-profit advocacy ... diabetes, today announced a grant from Beyond Type 1 ... for type 1 and other insulin-requiring diabetes.  ... developing innovative stem cell-derived cell replacement therapies with a ...
(Date:2/22/2017)... LEAWOOD, Kan. , Feb. 22, 2017  Aratana Therapeutics, ... licensing, development and commercialization of innovative biopharmaceutical products for companion ... 14, 2017 at 8:30 a.m. ET to discuss financial results ... 2016. Interested participants and investors may access ... dial-in: ...
(Date:2/22/2017)... ... February 22, 2017 , ... Park Systems , ... AFM Luncheon for all SPIE attendees and Park customers on Feb. ... block from the San Jose Convention Center. The luncheon will feature a talk ...
Breaking Biology Technology:
(Date:2/8/2017)... Report Highlights ... The global synthetic-biology market reached nearly $3.9 billion in ... a compound annual growth rate (CAGR) of 24.0% through 2021. ... for synthetic biology. - Analyses of global market trends, with ... annual growth rates (CAGRs) through 2021. - Coverage of core ...
(Date:2/8/2017)... Feb. 7, 2017 Report Highlights ... 2021 from $8.3 billion in 2016 at a compound ... 2021. Report Includes - An overview of the ... trends, with data from 2015 and 2016, and projections ... Segmentation of the market on the basis of product ...
(Date:2/7/2017)... Ind. , Feb. 7, 2017 Zimmer ... leader in musculoskeletal healthcare, will present at the LEERINK ... New York Palace Hotel on Wednesday, February 15, 2017 ... live webcast of the presentation can be accessed at ... replay following the conference via Zimmer Biomet,s Investor Relations ...
Breaking Biology News(10 mins):